27 Reductions in highly sensitive C-reactive protein were also observed with liraglutide and orlistat, as noted previously
We start with comprehensive blood work to analyze your current hormonal baseline
Patients should receive comprehensive education regarding signs and symptoms that could indicate malignancy and should be counseled to report any new symptoms or changes promptly
doi: 10.1210/clinem/dgaa863 Summary Keywords obesity, insulin-resistance, Tirzepatide, pathophysiology, GIP, GLP - 1, clinical trials, arterial hypertension Citation Corrao S, Pollicino C, Maggio D, Torres A and Argano C (2024) Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence
On the other hand, Fillon-Emery et al
Adults were randomly assigned, 1:1:1:2, to once-daily 6 mg orforglipron, 12 mg orforglipron, 36 mg orforglipron or placebo for 72 weeks